Research and Markets: Bronchiolitis Obliterans - Pipeline Review, H2 2012

Tue Feb 5, 2013 6:38am EST

* Reuters is not responsible for the content in this press release.

DUBLIN--(Business Wire)--

Research and Markets

( has announced
the addition of Global Markets Direct's new report "Bronchiolitis Obliterans -
Pipeline Review, H2 2012" to their offering. 

Global Markets Direct's, 'Bronchiolitis Obliterans - Pipeline Review, H2 2012',
provides an overview of the indication's therapeutic pipeline. This report
provides information on the therapeutic development for Bronchiolitis
Obliterans, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic
development for Bronchiolitis Obliterans.


- A snapshot of the global therapeutic scenario for Bronchiolitis Obliterans. 

- A review of the Bronchiolitis Obliterans products under development by
companies and universities/research institutes based on information derived from
company and industry-specific sources. 

- Coverage of products based on various stages of development ranging from
discovery till registration stages. 

- A feature on pipeline projects on the basis of monotherapy and combined

- Coverage of the Bronchiolitis Obliterans pipeline on the basis of route of
administration and molecule type. 

- Key discontinued pipeline projects. 

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under
development for Bronchiolitis Obliterans. 

- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage. 

- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline. 

- Devise corrective measures for pipeline projects by understanding
Bronchiolitis Obliterans pipeline depth and focus of Indication therapeutics. 

- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope. 

- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.

For more information visit

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.